Ascelia Pharma AB (publ) (ACE.ST) Research

Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.

Market snapshot

Symbol
ACE.ST
Price
$3.01
Day change
-0.83%
Market cap
$401.3M
P/E ratio
-5.09x
52-week range
2.53-5.23
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Elicera Therapeutics AB (publ) (ELIC.ST)
  • Mendus AB (publ) (IMMU.ST)
  • IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
  • Isofol Medical AB (publ) (ISOFOL.ST)
  • Intervacc AB (publ) (IVACC.ST)
  • Karolinska Development AB (publ) (KDEV.ST)
  • Lipum AB (publ) (LIPUM.ST)
  • Magle Chemoswed Holding AB (publ) (MAGLE.ST)

Open Ascelia Pharma AB (publ) (ACE.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.